Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.


HHS - 76836 - Frederick National Laboratory Advisory Committee to the National Cancer Institute - Authorized by Law
Hide Section - GENERAL INFORMATION

GENERAL INFORMATION

Committee NameFrederick National Laboratory Advisory Committee to the National Cancer InstituteAgency NameDepartment of Health and Human Services
Fiscal Year2020Committee Number76836
Original Establishment Date3/30/2011Committee StatusChartered
Actual Termination Date Committee URLhttp://deainfo.nci.nih.gov/advisory/fac/fac.htm
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*25
Current Charter Date3/30/2019Designated Fed Officer Position Title*Chief, Research Programs Review Branch, Division of Extramural Activities, NCI
Date Of Renewal Charter3/30/2021Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*Caron
Exempt From Renewal*NoDesignated Federal Officer Middle NameA.
Specific Termination AuthorityDesignated Federal Officer Last Name*Lyman
Establishment Authority*Authorized by LawDesignated Federal Officer SuffixPh.D.
Specific Establishment Authority*42 U.S.C. 285a-2(b)(7)Designated Federal Officer Phone*(240) 276-6348
Effective Date Of Authority*11/20/1985Designated Federal Officer Fax*240-276-7682
Exempt From EO 13875 Discretionary CmteNot ApplicableDesignated Federal Officer Email*lymanc@mail.nih.gov
Committee Type*Continuing
Presidential*No
Committee Function*Scientific Technical Program Advisory Board
Hide Section - RECOMMENDATION/JUSTIFICATIONS

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The Committee is composed of distinguished scientists from outside the NCI. The Committee provides scientific advice on existing and new projects (extramural and intramural) to be performed at the Frederick National Laboratory for Cancer Research (FNLCR). The Committee advises the Director, NCI and Associate Director, FNLCR about the intrinsic merit of the projects, and provides insight on proposed directions for ongoing and future work to be done at the FNLCR. This Committee will periodically review the existing portfolio of projects (extramural and intramural) at the FNLCR, evaluate their productivity, help determine which of these projects should be transitioned to more conventional mechanisms of support, i.e., (grants, contracts, cooperative agreements) and which should be considered for termination. The Committee represents viewpoints from the broader, extramural research community, and helps to assure that the operations at FNLCR are open, transparent, and in the best interest of the entire cancer research community. The Committee will submit a written description of the research and its recommendations to the Director, NCI, Deputy Directors, NCI, and the Associate Director, FNLCR. During the fiscal year, the Frederick National Laboratory Advisory Committee (FNLAC) was presented reports on various topics related to the organization of the FNLCR and the types of research that are being conducted. Committee discussions and reports included the spectrum of science conducted at the FNLCR; current and future work at the Frederick National Laboratory (FNL); Investigator-Initiated and Extramural Collaborative Research in the AIDS and Cancer Virus Program at FNLCR; strategies for developing RAS-like projects; role of FNLCR in NCI’s new Precision Medicine Initiatives; the Basic Science Program at FNLCR; progress to date and future directions for Human Papillomavirus (HPV) Serology; an overview of the Biopharmaceutical Development Program (BDP); distinctive capabilities of the Laboratory Animal Sciences Program (LASP); COVID-19 Serology and Immunology Capacity Building; an overview of Clinical and Foundational Serological Sciences; FNL Operations during the Pandemic; an overview of the COVID-19 Research Initiatives at FNL; recent progress of Immune Cell Engineering for the Extramural Community; and a discussion on new national programs at the FNLCR.
How is membership balanced?*The Committee will consist of up to 16 members, including the Chair, appointed by the Director, NCI. Members will be authorities knowledgeable in drug and vaccine development, clinical trials support, AIDS research, bioinformatics, genomics, nanotechnology, biological repositories, and basic research in immunology and infectious diseases. Additionally, a nonvoting representative from the National Cancer Advisory Board, the NCI Board of Scientific Advisors, and the NCI Board of Scientific Counselors (Basic Sciences and Clinical Sciences and Epidemiology) will serve for the duration of their terms on their respective Boards. Ex officio members include the NCI Deputy Directors, select NCI Division Directors and the Associate Director, FNLCR.
How frequent & relevant are cmte mtgs?*Meetings are held approximately three times each fiscal year. In FY20, the Committee met three times. Due to scheduling conflicts, the February 19, 2020 meeting was canceled, and it was not rescheduled. A full FNLAC in-person meeting was held on October 24, 2019 and two virtual meetings were held on May 21, 2020 and July 13, 2020. The FNLAC provides ongoing review of the relevance and effectiveness of the existing scientific programs (extramural and intramural) at the Frederick National Laboratory for Cancer Research. The FNLAC Ad Hoc RAS Working Group met virtually on December 18, 2019, April 28, 2020 and August 12, 2020 to continue to examine the scientific efforts of the phase II RAS Initiative project for the purpose of reporting progress and making suggestions to the Subcommittee and Parent committee for consideration. FNLAC Ad Hoc National Cryo-EM Facility Oversight Working Group met virtually on July 8, 2020 to continue to provide input on the National Cryo-EM Facility (NCEF), discuss potential expansion of services to biologists who are non-specialists to assess the effectiveness of the operations, and gauge the future need for cryo-EM and related technologies and services that support the extramural community. The FNLAC Ad Hoc NCI/DOE Collaborations Working Group met in-person on February 13, 2020 and held two virtual meetings on August 4, 2020 and August 14, 2020 to provide scientific evaluation of programs, projects and collaborations formed in support of or relevant to NCI/DOE collaborations. The FNLAC Ad Hoc Working Group on Cancer Models and Therapeutics Development met virtually on October 15, 2019 to discuss the issues, challenges, and activities of the NCI Patient-Derived Models Repository (PDMR). The FNLAC NCI Task Force to Evaluate the NCI/DOE Collaboration met virtually on July 31, 2020, August 17, 2020, August 31, 2020, September 4, 2020 and September 8, 2020 to determine if the NCI/DOE collaboration should continue and if so, what directions it should take.
Why advice can't be obtained elsewhere?*This Committee is composed of recognized biomedical research authorities from outside the NIH in order to secure unbiased and objective evaluation of research performed at FNLCR. Their recommendations are invaluable because the complex nature of the research requires a unique balance and breadth of expertise not available at NIH or from other established sources.
Why close or partially close meetings?N/A
Recommendation RemarksMeetings: The committee had three meetings in FY20. Due to scheduling conflicts, the February 19, 2020 meeting was canceled, and it was not rescheduled. There was an additional meeting held on May 21, 2020 to discuss COVID-19 Serology and Immunology Capacity Building and as well as to provide an overview of Clinical and Foundational Serological Sciences at the Frederick National Laboratory for Cancer Research.

Members: The terms for David I. Hirsh, Nilsa D. Ramirez Milan, Lisa M. Coussens, Kevin J. Cullen and Klaus M. Hahn have changed due to administration extensions. Sanford D. Markowitz resigned from the committee on 10/16/2019. As such, their term of service end dates are different than what was reported on the FY19 ACR. The terms for Lawrence Marnett, Robert Grossman, and David Hirsh are longer than the charter allows due to their reappointment to the FNLAC given their specific scientific expertise and the need to assure continuity in the functions of the FNLAC and the deliberation of issues brought before the Board.

Ex Officio Members: The terms for Dinah S. Singer and Tom Misteli were extended. As such, their term of service end dates are different than what was reported on the FY19 ACR. The term for Douglas R. Lowy changed due to a reappointment as an Ex Officio Member after serving as NCI Acting Director. As such, his term of service start and end dates are different than what was reported on the FY19 ACR.

The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute.
Hide Section - PERFORMANCE MEASURES

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*No
Outcome Trust In GovernmentNoAction Reallocate ResourcesNo
Outcome Major Policy ChangesNoAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryNoAction OtherYes
Outcome Increased Customer SatisfactionNoAction CommentThe committee continues to review the state of research (extramural and intramural) at the Frederick National Laboratory for Cancer Research (FNLCR) and make recommendations for the best use of its capabilities and infrastructure. They reviewed major new projects proposed to be performed at FNLCR and periodically review the existing portfolio of projects at FNLCR. The Committee helped to assure that the operations at FNLCR are open, transparent, and in the best interests of the entire cancer research community. The Committee also considered proposed research and will provide advice as to whether the FNLCR is the best mechanism for carrying out these projects which it deems to be of merit and to be consistent with the mission of the National Cancer Institute and FNLCR. There were specific discussions regarding the spectrum of science conducted at the FNLCR; current and future perspectives of FNLCR; current and future work at the Frederick National Laboratory (FNL); Investigator-Initiated and Extramural Collaborative Research in the AIDS and Cancer Virus Program at FNLCR; strategies for developing RAS-like projects; role of FNLCR in NCI’s new Precision Medicine Initiatives; the Basic Science Program at FNLCR; progress to date and future directions for Human Papillomavirus (HPV) Serology; an overview of the Biopharmaceutical Development Program (BDP); distinctive capabilities of the Laboratory Animal Sciences Program (LASP); COVID-19 Serology and Immunology Capacity Building; an overview of Clinical and Foundational Serological Sciences; FNL Operations during the Pandemic; an overview of the COVID-19 Research Initiatives at FNL; recent progress of Immune Cell Engineering for the Extramural Community; and a discussion on new national programs at the FNLCR. FNLAC unanimously approved establishing a FNLAC NCI–DOE Collaborations Task Force ad hoc Working Group at their October 24, 2019 meeting to determine if the NCI-DOE collaboration should continue and if so, what directions it should take. The Task Force is expected to include an in-depth technical review of all established projects as well as provide insights and observations on how the pilots, programs, projects, and collaborations, formed to date, have proceeded and indicate if the NCI/DOE collaborations should continue into years four and five and beyond. At their May 21, 2020 meeting, the FNLAC received several updates regarding the NCI response to COVID-19 to develop, validate, improve, and implement serological testing and associated technologies. These efforts were outlined in three areas. 1) Serology and Immunology Capacity Building – the use of FNLCR by NIAID to respond rapidly to epidemics and the use of FNLCR expertise in serology as a response to COVID-19 which pivots the HPV serology laboratory to SARS-CoV-2 serology devices; assists FDA in evaluating commercial SARS-CoV-2 serology devices; and the need to understand SARS-CoV-2 serology and how it may be even more important in the future. 2) Clinical Serological Sciences – modifications to NCI clinical trial processes; a compassionate use study on Tocilizumab; and a national COVID-19 natural history study. 3) Foundational Serological Sciences - establishing a Serological Sciences Network for COVID-19 to support expanding the serological testing capacity and research characterizing the immune response to SARS-CoV-2 infection and enhancing collaborative efforts to rapidly expand testing capacity in diverse geographical areas, develop novel serological assays, and enhance understanding of the innate and adaptive immune response to SARS-CoV2 infection. FNLAC confirmed that the FNLCR was on course in its COVID-19 response and other activities. At their July 13, 2020 meeting, the FNLAC participated in a round robin discussion providing input on the most important needs and promising opportunities in cancer research that are challenging to address on an individual research laboratory level. FNLAC members identified and provided a brief background about a problem in cancer research and provided a rationale for a program to address this problem that would be supported by the FNLCR.
Outcome Implement Laws/Reg RequirementsNoGrants Review*No
Outcome OtherNoNumber Of Grants Reviewed0
Outcome CommentBased on the recommendations of this committee, effective direction of the activities at the FNLCR has the potential to provide significant advances in cancer research and public health. The projects and programs at FNLCR, for which this Committee provides advice, could lead to new approaches and tools for cancer investigation, prevention, diagnosis and therapeutic interventions. The results and technologies may be applicable to other human health concerns.Number Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentNIH supported basic and clinical research accomplishments often take many years to unfold into new diagnostic tests and new ways to treat and prevent diseases.Grants Review CommentN/A
Number Of Recommendations*40Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentIn addition to a number of general recommendations, the committee recommended specifically a motion to establish a FNLAC NCI–DOE Collaborations Task Force. This motion was approved unanimously.Access Agency WebsiteYes
% of Recs Fully Implemented*0.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentDue to the large breadth and complexity of the recommendations made by this committee, NCI staff is unable to determine which recommendations have been fully or partially implemented solely in response to this committee’s activities.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*0.00%Access PublicationsYes
% of Recs Partially Implemented CommentDue to the complexity of the issues and the role of this committee, staff is unable to determine which recommendations have been fully or partially implemented solely in response to this committee’s activities.Access OtherYes
Agency Feedback*YesAccess CommentInformation on the FNLAC can be found at the NCI Division of Extramural Activities: Advisory Boards and Groups website at http://deainfo.nci.nih.gov/advisory/fac/fac.htm. Each NCI committee’s charter, minutes, agenda, roster, future meeting dates, meeting PowerPoint presentations and reports is located here. Additionally, the public may view the FNLAC meetings via the NIH Videocast at the following website: http://videocast.nih.gov/.
Agency Feedback Comment*At each meeting, the NCI Director, the NCI Acting Director, and NCI leaders provide a report to the Committee members.Narrative Description*The goal of NIH research is to acquire new knowledge to help prevent, detect, diagnose, and treat disease and disability, from the rarest genetic disorder to the common cold. The NIH mission is to uncover new knowledge that will lead to better health for everyone. NIH works toward that mission by the Frederick National Laboratory Advisory Committee (FNLAC) to the National Cancer Institute. The Committee will review major new projects proposed to be performed at Frederick National Laboratory for Cancer Research (FNLCR) and advise the Director, NCI and Associate Director, FNLCR about the intrinsic merit of the projects (extramural and intramural) and about whether they should be done at the FNLCR. In addition, this Committee will periodically review the existing portfolio of projects (extramural and intramural) at FNLCR, evaluate their productivity, help determine which of these projects should be transitioned to more conventional mechanisms of support, i.e., (grants, contracts, cooperative agreements) and which should be considered for termination. The Committee will help to assure that the operations at FNLCR are open, transparent, and in the best interest of the entire cancer research community. The Committee will submit a written description of the research and its recommendations to the Director, NCI, Deputy Directors, NCI, and the Associate Director, FNLCR.
Hide Section - COSTS

COSTS

Payments to Non-Federal Members*$5,600.00Est Payments to Non-Fed Members Next FY*$5,600.00
Payments to Federal Members*$13,094.00Est. Payments to Fed Members Next FY*$13,094.00
Payments to Federal Staff*$53,069.00Estimated Payments to Federal Staff*$47,055.00
Payments to Consultants*$4,600.00Est. Payments to Consultants Next FY*$4,600.00
Travel Reimb. For Non-Federal Members*$5,330.00Est Travel Reimb Non-Fed Members nextFY*$5,361.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$0.00
Travel Reimb. For Consultants*$6,979.00Est Travel Reimb to Consultants Next FY*$7,024.00
Other Costs$105,573.00Est. Other Costs Next FY*$106,629.00
Total Costs$194,245.00Est. Total Next FY*$189,363.00
Federal Staff Support (FTE)*0.30Est. Fed Staff Support Next FY*0.30
Cost RemarksActual Costs: The total operating costs for FY20 increased due to an increase in the number of working group meetings during the fiscal year. Ex Officio Member Costs: Daily salary costs have been estimated for Ex Officio members. The dollar figure represents a portion of their annual salary. No funds have been transferred between the committee and the agency. No additional funds are paid to Federal employee due to membership on this committee.Est Cost Remarks
Hide Section - Interest Areas

Interest Areas

Category
Area
Medicine
Health and Health Research
Research
Basic Research
Research and Development
Hide Section - MEMBERS,MEETINGS AND ADVISORY REPORTS

MEMBERS,MEETINGS AND ADVISORY REPORTS

To View all the members, meetings and advisory reports for this committee please click here
Hide Section - CHARTERS AND RELATED DOCS

CHARTERS AND RELATED DOCS

No Documents Found
Hide Section - DATA FROM PREVIOUS YEARS

DATA FROM PREVIOUS YEARS

Committee

Data from Previous Years

 
ActionCommittee System IDCommittee NameFiscal Year
 COM-036726Frederick National Laboratory Advisory Committee to the National Cancer Institute2019
 COM-034920Frederick National Laboratory Advisory Committee to the National Cancer Institute2018
 COM-001882Frederick National Laboratory Advisory Committee to the National Cancer Institute2017
 COM-002365Frederick National Laboratory Advisory Committee to the National Cancer Institute2016
 COM-003889Frederick National Laboratory Advisory Committee to the National Cancer Institute2015
 COM-004722NCI-Frederick Advisory Committee2014
 COM-006239NCI-Frederick Advisory Committee2013
 COM-006636NCI-Frederick Advisory Committee2012
 COM-008297NCI-Frederick Advisory Committee2011